AdvaMed Applauds Senate Vote on MDUFA Reauthorization
WASHINGTON, D.C. (Aug. 3) - The Advanced Medical Technology Association (AdvaMed) issued the following statement from President and CEO Scott Whitaker regarding Senate passage of the FDA Reauthorization Act of 2017:
"AdvaMed commends the Senate for their vote today on the FDA Reauthorization Act. Passage of this important legislation will enable FDA to continue its critical mission of ensuring safe and effective medical devices and diagnostics remain available to patients everywhere.
"The robust FDA performance goals, process improvements, increased accountability and additional resources provided for under the new user fee agreement represent a victory for the agency, innovation and, most importantly, patients. The bill also includes pro-innovation provisions to improve the FDA inspections process and streamline device accessory classification.
"We urge the president to move swiftly in signing the bill into law, and we look forward to working with FDA to implement the legislation and continue to bring life-saving technologies to patients."
Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.